The Missing Diagnosis
Is Inflammation Driving Your Depression and Anxiety?
For anyone who has tried the medication, done the therapy, and still felt like something biological was being missed.
If you’ve done the work. If you’ve been in therapy, tried the medication, made the lifestyle changes — and you’re still not where you expected to be. If after all of it you still have mornings that feel impossible, a fatigue that doesn’t respond to rest, a fog that makes you feel less like yourself than you used to be.
You’re not imagining it. And you may not have been given the full picture.
A meaningful proportion of people with depression and anxiety have biological contributors that are actively working against their recovery — inflammation, nutritional deficiencies, thyroid dysfunction, insulin resistance, undiagnosed sleep disorders, gut dysbiosis — that standard psychiatric workups simply don’t look for. When those contributors go unaddressed, even skilled, thoughtful psychiatric care is fighting upstream against a biological current it can’t see.
This isn’t an argument against medication or therapy. Those interventions genuinely help people and sometimes they’re the most important thing. It’s an argument for asking one question that rarely gets asked: is there a body-level story underneath the mind-level diagnosis?
I think about one patient in particular when I write this. He had been on two antidepressants. They helped — partially, incompletely. Enough to function. Not enough to feel like himself.
His psychiatrist was thoughtful and his therapist was skilled. The work was real and it mattered. But after three years he still had mornings where getting out of bed felt like climbing out of quicksand. Still had a kind of fatigue that no amount of sleep touched. Still had a cognitive fog that made his work slower, harder, and less satisfying than it had ever been.
He came to see me because his wife had read something about the gut-brain connection and thought it was worth exploring. He was skeptical. But he came.
His labs told a story nobody had connected before. His high-sensitivity CRP: the most sensitive inflammatory marker on a standard panel was 4.8 mg/L. His fasting insulin was elevated. His vitamin D was 19 ng/mL. His ferritin was 14, borderline depleted. His comprehensive stool analysis showed significant gut dysbiosis.
None of these were part of his psychiatric workup. None had been checked.
We didn’t replace his psychiatrist or his therapist. We didn’t take him off his medication. We addressed the biology underneath. Six months later he described himself as feeling, for the first time in years, genuinely well, not managed, not functional, but well.
I want to be clear about what this story is and isn’t. It is not an argument that depression and anxiety are never truly psychiatric conditions, or that medication and therapy are the wrong approach. They are often exactly the right approach. The research on cognitive behavioral therapy is among the strongest in medicine. Antidepressants help a significant proportion of the people who take them.
But here is what I know from clinical practice: a meaningful proportion of people with depression and anxiety have unaddressed biological contributors: inflammation, nutritional deficiencies, thyroid dysfunction, insulin resistance, undiagnosed sleep disorders, gut dysbiosis, that are actively working against recovery. When those contributors go unidentified and untreated, even the most skilled psychiatric care is fighting upstream against a biological current.
This masterclass is about that question and what it looks like when someone actually takes the time to answer it.
Part 1: Recognizing the Pattern
Why the Biology of Depression Is More Complex Than the Model Suggests
The model most people carry for depression ,that it is caused by low serotonin and corrected by medications that raise it was always more of a working hypothesis than settled science. It served a purpose: it destigmatized depression as a biological brain condition rather than a character weakness. But the simplification has cost us.
A 2023 umbrella review published in Molecular Psychiatry — one of the most discussed papers in psychiatry in recent years — found no consistent evidence across multiple research areas that depression is associated with lowered serotonin concentration or activity [1]. This doesn’t mean SSRIs don’t help people, they clearly do. But it does mean the mechanism is more complex than a simple deficit, and that focusing exclusively on the serotonin pathway while ignoring other biological contributors leaves real opportunities unaddressed.
What the last decade of research has been moving toward is a more heterogeneous model: one that recognizes multiple distinct biological subtypes of depression with different drivers and, potentially, different optimal treatments.
The Inflammatory Subtype
The most compelling emerging framework is what researchers call immuno-metabolic or inflammatory depression. The concept: for a meaningful subset of people with major depressive disorder, estimates in the research range from 25–40%. Depression is driven primarily by systemic inflammation rather than neurotransmitter imbalance [2].
The mechanisms are documented. Pro-inflammatory cytokines: the chemical messengers of immune activation cross the blood-brain barrier and directly alter brain function. They impair the production of serotonin, dopamine, and other neurotransmitters. They increase glutamate activity, creating a neurotoxic environment. They activate the HPA axis, chronically elevating cortisol. They disrupt the prefrontal cortex and hippocampus, regions directly involved in mood regulation, stress response, and memory [2].
What triggers this inflammatory state? The same drivers of systemic inflammation more broadly: metabolic dysfunction, visceral adiposity, insulin resistance, poor sleep, gut dysbiosis, chronic stress, nutritional deficiencies. Which means these are the same conditions this series has been tracking. This is the link that makes integrative medicine not an add-on but a central part of the picture.
Clinically, inflammatory depression tends to present with specific features: prominent fatigue and low energy more than classic sadness, psychomotor slowing, cognitive impairment, and atypical features like increased sleep and increased appetite. Elevated high-sensitivity CRP in someone with depression is a meaningful clinical signal that inflammation is part of the story [2].
The Gut-Brain Axis
The relationship between gut health and mental health has moved from fringe to firmly peer-reviewed territory. The evidence base is now substantial enough that it has been reviewed in major journals including Molecular Psychiatry and Clinical Psychology Review [3].
The biology: the gut microbiome communicates with the brain through multiple channels simultaneously: the vagus nerve (a direct neural highway), the immune system (roughly 70% of immune cells reside in the gut), and through the production of neurotransmitter precursors and metabolites. Approximately 90% of the body’s serotonin is produced in the gut, not the brain [5]. Short-chain fatty acids produced by gut bacteria regulate inflammation and directly influence brain function. The microbiome modulates the HPA axis and affects tryptophan metabolism: the pathway that produces serotonin and, under inflammatory conditions, neurotoxic compounds instead [3].
Consistent findings in the research: people with depression and anxiety have measurably different gut microbiome composition than matched controls. Specifically, lower abundance of the anti-inflammatory, butyrate-producing bacteria (Faecalibacterium, Coprococcus) and increased pathobionts associated with inflammation [3].
This doesn’t mean gut health is the whole story of depression. It means it is part of the story for a meaningful proportion of people and one that is not evaluated in any standard psychiatric workup.
The Nutritional Gaps
Several nutritional deficiencies have direct, documented relationships with depression and anxiety. These are not speculative associations:
Vitamin D deficiency is associated with depression across multiple large population studies. Vitamin D receptors are present throughout the brain, including in regions directly involved in mood regulation. Supplementation trials in people with documented deficiency show meaningful improvement in depressive symptoms [6].
Iron deficiency — even without frank anemia — impairs dopamine synthesis, disrupts sleep architecture, causes cognitive slowing, and produces fatigue patterns that are indistinguishable from depression. Ferritin below 30 ng/mL is functionally significant even when hemoglobin looks normal. (Note: this threshold is above many standard lab reference ranges but is consistent with functional medicine practice and supported by neurological research.)
Magnesium deficiency reduces GABA receptor sensitivity. GABA is the brain’s primary calming neurotransmitter: Magnesium deficiency elevates cortisol, and impairs sleep. It is likely the most common nutritional deficiency that most people have never been tested for.
Omega-3 fatty acids (EPA specifically) have anti-inflammatory and neurological effects that are clinically meaningful in depression. Multiple meta-analyses support EPA supplementation as an adjunct in depression, particularly for inflammatory presentations [7].
B12 and folate are both essential for methylation: the biochemical process underlying neurotransmitter synthesis. B12 deficiency is common in people on metformin, older adults, and those following plant-based diets. It produces mood, cognitive, and neurological symptoms that are consistently mistaken for primary psychiatric illness.
Part 2: This Is Also In Your Body
The Conversation That Rarely Happens in Psychiatry
I want to be careful here, because this section is not a critique of psychiatric care. Clinicians working in mental health are doing important work under significant systemic constraints, and psychiatric medication genuinely saves lives.
But the standard psychiatric workup for depression and anxiety — even a thorough one — does not typically include inflammatory markers, metabolic panels, nutritional assessments, sleep studies, thyroid antibodies, or gut health evaluation. Not because these aren’t relevant, but because the system wasn’t designed to integrate them. The model of mental health care was built largely separately from the model of physical health care, and the two have been slow to converge.
The result is that a person with inflammatory depression, vitamin D deficiency, undiagnosed sleep apnea, and subclinical hypothyroidism may spend years cycling through antidepressants while the biological substrate driving their symptoms goes entirely unaddressed.
The immunometabolic depression research by Milaneschi, Lamers, Berk, and Penninx laid out clearly how biological dysregulations, particularly inflammatory and metabolic, map consistently to specific depressive symptom patterns, and how these biological subtypes may respond differently to different treatments [2]. The implication is not that we should abandon antidepressants. It’s that we should stop treating all depression as if it has the same biological cause.
The brain is an organ. It responds to what’s happening in the body it lives in. Addressing that body is part of treating the brain.
✦ Subscribe to Continue Reading
The rest of this masterclass — including the complete biological workup I run for patients presenting with depression or anxiety, the interventions with the strongest evidence for the inflammatory subtype, the dietary and supplement protocol, the gut health approach, and how to bring this conversation to your existing providers — is available to paid subscribers.
Every piece in this series is written by our clinical team, grounded in peer-reviewed evidence, and built for people who feel like something is being missed in their care.
Already a subscriber? Continue below.
Part 3: What Good Testing Actually Looks Like
The Biological Workup That’s Missing
A comprehensive integrative evaluation for depression and anxiety starts where standard psychiatry often ends. Here’s what I include:
High-sensitivity CRP (hs-CRP) — the most accessible inflammatory marker in a standard panel. Below 1 mg/L is low risk; 1–3 mg/L is moderate; above 3 mg/L suggests meaningful systemic inflammation. People with depression and elevated CRP are less likely to respond to SSRIs and more likely to benefit from anti-inflammatory interventions [2]. This single number helps me understand which direction the conversation needs to go.
Full thyroid panel — TSH, free T3, free T4, TPO antibodies. As covered in the previous masterclass, TSH alone is insufficient. Hypothyroidism and Hashimoto’s are among the most commonly missed biological drivers of depression, fatigue, and brain fog. An elevated TPO antibody alongside depressive symptoms is a clinically significant finding.
Full iron panel — ferritin, serum iron, transferrin saturation, and TIBC. Ferritin below 30 ng/mL is functionally relevant to mood and cognition even when hemoglobin is normal. This threshold is above many standard lab reference ranges but is consistent with the neurological research on iron and brain function. This is routinely missed because standard “anemia screens” look only at hemoglobin.
25-hydroxyvitamin D — I’m not looking for the lab’s lower limit of “normal” (often 20 ng/mL). I’m looking for levels above 50–60 ng/mL in patients with mood symptoms. The clinical difference between 25 ng/mL and 60 ng/mL is not trivial.
Fasting glucose, fasting insulin, HOMA-IR — insulin resistance is independently associated with depression, and the relationship is bidirectional. HOMA-IR (calculated from fasting glucose and insulin) above 1.9–2.0 suggests early insulin resistance; above 2.9 is consistent with meaningful resistance. Addressing insulin resistance often improves mood, energy, and cognitive function even without direct psychiatric intervention.
Homocysteine — elevated homocysteine reflects impaired methylation, often due to B12, folate, or B6 deficiency. It is neurotoxic and associated with depression and cognitive decline. It’s easily treated when identified and easy to miss when not tested.
Omega-3 index — measures EPA and DHA as a percentage of red blood cell membranes, reflecting long-term status. Below 4% is associated with increased depression risk; the therapeutic range is generally above 8%. This is a more meaningful measure than a food recall.
Comprehensive metabolic panel and liver enzymes — liver function affects drug metabolism, hormone processing, and toxin clearance. Impaired liver function can undermine psychiatric medication efficacy and overall metabolic resilience.
Sleep evaluation — as covered in the previous masterclass, comorbid sleep apnea in depression is common, frequently missed, and when treated often produces dramatic improvements in mood. If fatigue and non-restorative sleep are prominent features, a sleep study is not optional.
Gut health assessment — comprehensive stool analysis can assess microbial diversity, inflammatory markers in the gut, and intestinal permeability markers. I use these selectively, in patients where gut symptoms coexist with mood symptoms, rather than universally. The evidence for clinical actionability is growing and the testing is still evolving — I’m honest with patients about where that line is.
Part 4: What Actually Moves the Needle
The Anti-Inflammatory Foundation
For patients where inflammation appears to be a primary driver, the anti-inflammatory intervention is the therapeutic anchor.
Dietary pattern — the Mediterranean dietary pattern has the most robust evidence for mental health benefit. The SMILES trial( a randomized controlled trial published in BMC Medicine) demonstrated that dietary intervention targeting the Mediterranean pattern produced significant improvement in depression scores compared to a social support control condition, with 32% of dietary intervention participants achieving remission [4]. This was a clinical trial showing that food functions as medicine for depression. The mechanisms are multiple: reduced inflammatory dietary burden, improved omega-3 to omega-6 ratio, better gut microbiome diversity, improved insulin sensitivity, and better provision of the nutrients required for neurotransmitter synthesis.
Omega-3 supplementation (EPA specifically) at 1–2g EPA daily has shown consistent benefit as an adjunct in depression across multiple meta-analyses, with the strongest effects in inflammatory presentations [7]. This is not a subtle supplement effect. In the right patient it is a clinically meaningful one.
Exercise — the antidepressant effect of exercise is now one of the most consistently replicated findings in psychiatric research. A 2024 network meta-analysis published in the BMJ found that exercise interventions were significantly more effective than active controls for depression, anxiety, and psychological distress [8]. The mechanisms are multiple: neurogenesis, BDNF upregulation, HPA axis regulation, reduction of inflammatory markers, and improvement in sleep architecture. 30–45 minutes of moderate-to-vigorous aerobic exercise three or more times weekly produces effects that are clinically comparable to antidepressants for mild-to-moderate depression. This is not a lifestyle suggestion. It is a clinical intervention.
Gut microbiome support — the intervention with the most consistent evidence is dietary: increased fiber diversity, fermented foods (yogurt, kefir, kimchi, sauerkraut), polyphenol-rich foods (berries, olive oil, legumes), and reduced ultra-processed food. The dietary pattern that supports the microbiome and the dietary pattern that reduces inflammation are essentially the same pattern, which is one reason the Mediterranean approach keeps appearing.
Probiotic supplementation has a growing evidence base specifically for depression and anxiety. Multi-strain formulations appear more effective than single-strain products. The evidence is promising. I recommend probiotic support selectively for patients with clear gut symptoms alongside mood symptoms, not universally.
The Nutritional Protocol
Vitamin D — for patients with levels below 40 ng/mL and mood symptoms, I supplement to achieve levels above 60 ng/mL. This typically requires 3,000–5,000 IU daily with monitoring at 3 months [6].
Magnesium glycinate — 200–400mg at night. Glycinate form for better absorption; timing to support sleep alongside mood. This is one of the most consistently helpful interventions I see in practice for the anxious, poorly sleeping patient with muscle tension and nighttime racing thoughts.
B12 and methylfolate — for anyone with elevated homocysteine, documented B12 deficiency, or who is on metformin (which depletes B12 through gut absorption impairment). Methylcobalamin rather than cyanocobalamin for better neurological utilization; methylfolate rather than folic acid for those with MTHFR variants that impair conversion.
EPA-rich omega-3 — 1–2g EPA daily as an adjunct to existing treatment, particularly in inflammatory presentations [7].
Iron — for anyone with ferritin below 30 ng/mL and mood or cognitive symptoms. Pair with vitamin C for absorption. Retest at 3 months. The target ferritin for neurological function optimization is above 50 ng/mL, which is above many standard lab reference ranges but consistent with functional and neurological medicine research.
Ashwagandha (KSM-66) — for anxiety with prominent HPA axis activation — the “tired but wired” pattern, anxiety worse in the evening, difficulty settling. The evidence for cortisol reduction and anxiety symptom improvement is among the most consistent in the adaptogen category [9]. One important note: ashwagandha is contraindicated in pregnancy and should be used with caution in people with thyroid conditions or those on thyroid medication, as it can influence thyroid hormone levels. Given the thyroid issues this patient population often carries, discuss this with your provider before starting.
When Medication Is the Right Answer
For moderate-to-severe depression, suicidal ideation, panic disorder, OCD, and conditions where the evidence for psychiatric medication is strong medication is appropriate and often necessary. Full stop. The biological contributors I’ve described in this masterclass are not an alternative to psychiatric care for serious mental illness. They are an upstream intervention, a way to optimize the biology on which that care operates.
What I push back on is the use of psychiatric medication as the first and only response, without investigating whether there is a modifiable biological contributor that — if addressed — could meaningfully change the treatment picture. That investigation is not alternative medicine. It is integrative medicine: looking at the whole system before assuming which single lever will fix it.
My approach for a patient presenting with depression or anxiety: comprehensive biological workup as above. Identify and address modifiable contributors sometimes alongside existing psychiatric medication, sometimes first. Refer to or collaborate with psychiatry when symptoms are severe, when suicidality is present, or when biological intervention alone is clearly insufficient. The goal is not to choose between the medical model and the integrative model. It is to use both, thoughtfully.
Part 5: Retesting and What to Watch
The 90-Day and 6-Month Framework
At 90 days: recheck hs-CRP (should be trending down if anti-inflammatory interventions are working), vitamin D (to confirm dose is achieving target levels), ferritin (to confirm iron repletion), and homocysteine if elevated at baseline.
For mood tracking, I use validated scales — PHQ-9 for depression, GAD-7 for anxiety — at baseline and at 90 days. These give objective data to compare with subjective experience, which often diverges in interesting ways. Some patients feel meaningfully better before their scores reflect it; others score better while not yet feeling it subjectively. Both directions tell me something useful.
At 6 months: reassess the full metabolic picture. Has insulin resistance improved? Are inflammatory markers stable or continuing to improve? Is sleep better? Has gut symptomatology changed? These are the systems-level outcomes that tell me whether the biological terrain is genuinely shifting.
Track between labs: morning mood before the day’s demands have had a chance to influence it, sleep quality, energy at mid-morning, appetite, social motivation, cognitive sharpness, and physical symptoms — gut comfort, headaches, muscle tension. The pattern across these gives a fuller picture than any single question about how you’re feeling.
Return sooner if: suicidal ideation develops or intensifies, depressive symptoms significantly worsen despite intervention, or new physical symptoms appear. The biological contributors I’ve described are real — but they are not the whole story for everyone, and escalating psychiatric care when it’s needed is always the right call.
Bringing This to Your Existing Providers
If you’re already working with a psychiatrist or therapist, this information doesn’t have to create tension in that relationship. Most thoughtful clinicians are genuinely interested in whether there are biological contributors to their patient’s symptoms — they simply may not have the time or specialty knowledge to investigate them systematically. Asking your psychiatrist to check hs-CRP, vitamin D, thyroid antibodies, and ferritin is a reasonable clinical request. Sharing that you’re working with an integrative medicine practitioner to address these alongside your psychiatric care is a collaborative frame, not a challenging one.
Where to Go From Here
The brain is a biological organ. It is affected by what you eat, how you sleep, what’s happening in your gut, how your immune system is functioning, what your hormones are doing, and whether your cells are receiving adequate nutrients. None of this makes depression “your fault.” All of it makes it more responsive to intervention than the standard model suggests.
I see people regularly who have been told their symptoms are a fixed feature of their brain chemistry. People who have learned to manage rather than expect resolution, people who stopped looking for a cause because they were told there wasn’t one. Sometimes that’s right. But often the current system allows us to discover there is something biological underneath that hasn’t been looked at.
That’s what this series is here to help you find.
If you’re ready to look at the whole picture, we’re here for that conversation.
Book a Consultation with Heal Integrative Wellness
Sources
Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Molecular Psychiatry. 2023;28(8):3243–3256. doi:10.1038/s41380-022-01661-0
Milaneschi Y, Lamers F, Berk M, Penninx BWJH. Depression heterogeneity and its biological underpinnings: toward immunometabolic depression. Biological Psychiatry. 2020;88(5):369–380. doi:10.1016/j.biopsych.2020.01.014
Simpson CA, Diaz-Arteche C, Eliby D, Schwartz OS, Simmons JG, Cowan CSM. The gut microbiota in anxiety and depression — a systematic review. Clinical Psychology Review. 2021;83:101943. doi:10.1016/j.cpr.2020.101943
Jacka FN, O’Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Medicine. 2017;15(1):23. doi:10.1186/s12916-017-0791-y
Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell. 2015;161(2):264–276. doi:10.1016/j.cell.2015.02.047
Shaffer JA, Edmondson D, Wasson LT, et al. Vitamin D supplementation for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials. Psychosomatic Medicine. 2014;76(3):190–196. doi:10.1097/PSY.0000000000000044
Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Translational Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5
Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847. doi:10.1136/bmj-2023-075847
Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine. 2012;34(3):255–262. doi:10.4103/0253-7176.106022
This masterclass is written and reviewed by the clinical team at Heal Integrative Wellness. It is for educational purposes and does not replace individualized medical advice. If you are experiencing thoughts of self-harm or suicide, please contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
© Heal Integrative Wellness — Series 3: The First Diagnosis